Valvular Heart Disease in Pregnancy: Anticoagulation and the Role of Percutaneous Treatment

Curr Probl Cardiol. 2021 Mar;46(3):100679. doi: 10.1016/j.cpcardiol.2020.100679. Epub 2020 Jul 30.

Abstract

Valvular heart disease is present in about 1% of pregnancies, and it poses a management challenge as both fetal and maternal lives are at risk of complications. Pregnancy is associated with significant hemodynamic changes, which can compromise the cardiac status in women with underlying valvular disorders. Management of valvular heart diseases has undergone considerable innovation and advancement with newer techniques, approaches and devices being employed. The decision regarding the management of anticoagulation, especially in patients with prosthetic valves, raises distinct questions and challenges. In this review, we describe the management of common valvular heart diseases encountered during pregnancy, role of percutaneous catheter based therapeutic interventions, the importance of a team-based approach, and the challenges given existing gaps in the literature.

Publication types

  • Review

MeSH terms

  • Anticoagulants / administration & dosage
  • Female
  • Heart Valve Diseases* / drug therapy
  • Heart Valve Prosthesis*
  • Hemodynamics
  • Humans
  • Pregnancy
  • Pregnancy Complications, Cardiovascular* / drug therapy
  • Pregnancy Complications, Cardiovascular* / therapy
  • Risk Factors

Substances

  • Anticoagulants